argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced an Extraordinary General Meeting for shareholders on 18 November 2025 at 14:00 CET at Freshfields offices, Strawinskylaan 10, Amsterdam.
The meeting will consider the proposed adoption of a revised remuneration policy. The formal convocation includes details on in-person attendance, proxy voting, registration requirements and the e-voting system. All meeting documents and the agenda are available on argenx.com and abnamro.com/evoting, and may be inspected at argenx offices or requested by emailing legal@argenx.com. Shareholders are encouraged to vote by electronic proxy as described in the convocation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARGX declined 1.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
October 3, 2025
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.
The shareholders and all other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
Agenda
argenx has proposed the adoption of a revised remuneration policy during the meeting. The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
BPetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When and where is argenx's Extraordinary General Meeting of shareholders (ARGX) scheduled?
What is the main agenda item at argenx's EGM on November 18, 2025 (ARGX)?
How can ARGX shareholders access the EGM convocation and voting information?
Can ARGX shareholders vote by proxy for the November 18, 2025 EGM (ARGX)?
How can I obtain a copy of the EGM agenda and ancillary documents for ARGX?
Is e-voting available for argenx's Extraordinary General Meeting (ARGX)?
